Первичный идиопатический гиперальдостеронизм в клинической практике
https://doi.org/10.14341/2071-8713-5122
Аннотация
Список литературы
1. Бельцевич Д.Г. (перевод). Первичный гиперальдостеронизм. Клинические рекомендации. Эндокринная хирургия 2008;2(3):6–10.
2. Дедов И.И., Мельниченко Г.А. Эндокринология. Национальное руководство. М.: ГЭОТАР-Медиа, 2009. 685 с.
3. Калинин А.П., Майстренко Н.А. Хирургия надпочечников. М.: Медицина, 2000.
4. Кеттайл В.М., Арки Р.А. Патофизиология эндокринной системы. Пер. с анг. СПб.-М.: «Невский Диалект» – «Издательство БИНОМ», 2001:115–118.
5. Левитская З.И., Вабищевич А.А., Перистая Е.В. Первичный идиопатический гиперальдостеронизм в клинической перспективе. Лечащий врач 2006;2:18–19.
6. Трошина Е.А., Бельцевич Д.Г., Молашенко Н.В. Диагностика и дифференциальная диагностика первичного гиперальдостеронизма. Клиническая медицина 2009;5:15–20.
7. Фадеев В.Ф., Бельцевич Д.Г., Рогаль Е.Ю., Молашенко Н.В., Мельниченко Г.А. Лечение гиперальдостеронизма. Проблемы эндокринологии 2010;3:42–44.
8. Чихладзе Н.М., Чазова И.Е. Симптоматические артериальные гипертонии. Диагностика и лечение. М.: Медицина, 2005.
9. An Endocrine Society Clinical Practice Guidelines. Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. J Clin. Endocrinol. Metab 2008;93:3266–3281.
10. Brilla C., Matsubara L., Weber K. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary aldosteronism. J Mol. Cell. Cardiol 1993;25:563–575.
11. Brilla C.G. Aldosterone and myocardial fibrosis in heart failure. Herz 2000;25:299–306.
12. Brilla C.G., Janicki J.S., Weber K.T. Impaired diastolic function and coronary reserve in genetic hypertension role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. American Heart Association. Circulation Research 1991;69:107–115.
13. Brilla C.G., Pick R., Tan L.B., Janicki J.S., Weber K.T. Remodeling of the rat right and left ventricles in experimental hypertension. Circ. Res 1990;67:1355–1364.
14. Calhoun D.A., Sharma K. The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol Clin 2010 Aug;28(3):517–27.
15. Chapman D., Weber K.T., Eghbali M. Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ. Res 1990; 67:787–794.
16. Chhokar V.S., Sun Y., Bhattacharya S.K., Ahokas R.A., Myers L.K., Xing Z., Smith R.A., Gerling I.C., Weber K.T. Loss of bone minerals and strength in rats with aldosteronism. Am J. Physiol. Heart. Circ. Physiol 2004 Nov;287(5):H2023–6.
17. Chitalia N., Weeg N., Antonios T.F.T. Aldosterone-producing adrenal adenoma and idiopathic intracranial hypertension – a pathogenetic link for aldosterone? QJM 2010;103:699–702.
18. Gaddam K., Corros C, Pimenta E. et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension 2010 May;55(5):1137–42. Epub. 2010, Mar 29.
19. Garthwaite S.M., McMahon E.G. The evolution of aldosterone antagonists. Mol. Cel. Endocrinol 2004;217:27–31.
20. Griffing G.T., McIntosh T., Berelowitz B., Hudson M., Salzman R., Manson J.A., Melby J.C. Plasma beta-endorphin levels in primary aldosteronism. J Clin. Endocrinol. Metab 1985 Feb;60(2):315–9.
21. Fallo F., Della Mea P., Sonino N. et al. Adiponectin and insulin sensitivity in primary aldosteronism. American Journal of Hypertension 2007;20(8):855–861.
22. Fallo F., Federspil G., Veglio F, Mulatero P. The metabolic syndrome in primary aldosteronism. Curr Diab Rep 2008 Feb;8(1):42–7.
23. Fallo F., Veglio F., Bertello C. et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin. Endocrin. Metabol 2006;91(2):454–459.
24. Funder J.W., Carey R.M., Fardella C., Gomez-Sanchez C.E., Mantero F., Stowasser M., Young W.F. Jr., Montori V.M., Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol. Metab 2008 Sep;93(9):3266–81.
25. Iacobellis G., Petramala L., Cotesta D. et al. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J Clin. Endocrinol. Metab 2010 May;95(5):2391–8. Epub 2010 Mar 1.
26. Jeon J.H., Kim K.Y., Kim J.H. et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB Journal 2008;22:1502–1511.
27. Karagiannis A., Tziomalos K., Papageorgiou A., Kakafika A.I., Pagourelias E.D., Anagnostis P., Athyros V.G., Mikhailidis D.P. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin. Pharmacother 2008 Mar;9(4):509–15.
28. Lastra-Lastra G., Sowers J.R., Restrepo-Erazo C. et al. Role of Aldosterone and angiotensin II in Insulin Resistance: An Update. Clin. Endocrinol 2009;71:1–6.
29. Menard J., Gonzalez M.F., Guyene T.T., Bissery A. Investigation of aldosterone-synthase inhibition in rats. J Hypertens 2006;24:1147–1155.
30. Mulatero P., Morello F., Veglio F. Genetics of primary aldosteronism. J Hypertens 2004;22:663–670.
31. Perraudin V., Delarue C., Lefebvre H., Do Rego J.L., Vaudry H., Kuhn J.M. Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies. J Clin. Endocrinol. Metab 2006 Apr;91(4):1566–72. Epub 2006 Jan 31.
32. Stehr C.B., Mellado R, Ocaranza MP, et al. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens 2010 Oct;28(10):2120–6.
33. Takeda Y., Furukawa К., Inaba S. et al. Genetic Analysis of Aldosterone Synthase in Patients with Idiopathic Hyperaldosteronism. J Clin Endocrinol Metab l999;84(5):1633–1637.
34. Tian Y., Balla Т., Baukal A.J. et al. Growth responses to angiotensin II in bovine adrenal glomerulosa cells. Am J Physiol (Endocrinol) 1995;268:135–144.
35. Urbanet R., Pilon C., Calcagno A. et al. Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism. J Clin. Endocrinol. Metab 2010 Aug;95(8):4037–42. Epub., 2010 May 19.
36. Weber K. Aldosterone and spironolactone in heart failure. N. Engl. J. Med 1999;341:753–5.
37. Weber K. Aldosterone in congestive heart failure. N. Engl. J. Med 2001;345:1689–97.
38. Weber K.T., Singh K.D., Hey J.C. Idiopathic intracranial hypertension with primary aldosteronism: report of 2 cases. Am J Med Sci 2002 Jul;324(1):45–50.
39. Whaley-Connell A., Johnson M.S., Sowers J.R. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog. Cardiovasc. Dis 2010 Mar-Apr;52(5):401–9.
40. Wong G.W., Krawczyk S.A., Kitidis-Mitrokostas C., Revett T., Gimeno R., Lodish H.F. Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-γ agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J 2008 Dec;416(2):161–77
41. Young W.F. Primary aldosteronism: renaissance of a syndrome. Clin. Endocrinol. (Oxf) 2007;66:607–618.
42. Young W.F.Jr., William F. Minireview: Primary Aldosteronism – Changing Concepts in Diagnosis and Treatment. Endocrinology 2003 Jun;144(6):2208–13.
Рецензия
Для цитирования:
Molashenko N.V., Troshina E.A. Первичный идиопатический гиперальдостеронизм в клинической практике. Ожирение и метаболизм. 2012;9(4):3-9. https://doi.org/10.14341/2071-8713-5122
For citation:
, Primary idiopathic hyperaldosteronism in clinical practice. Obesity and metabolism. 2012;9(4):3-9. (In Russ.) https://doi.org/10.14341/2071-8713-5122

Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).